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Abstract
Introduction. Infective endocarditis (IE) is a disease associated with high morbidity and mortality. Multiple risk factors 
have been identified for mortality in IE.
Material and methods. 21 patients diagnosed with IE between January 2018 and January 2019 were retrospectively 
analysed. All data was expressed as mean ± standard error (SE). Variables were analysed with chi-square, Fisher’s exact, 
and Mann-Whitney tests. A p-value < 0.05 was identified as statistically significant.
Results. Total mortality was 52.4% and in-hospital mortality was 28.6%. Patients who died in the course of IE were older 
compared to survivors (66.7 ± 19.8 years vs 70.8 ± 11.6). Staphylococci and Streptococci spp. were causative patho-
gens in 71.4% of cases of IE. Morphology was the most important feature that identified patients who died: white blood 
cells were higher in non-survivors (35.39 ± 14.36 vs 12.02 ± 4.67, p < 0.05); haemoglobin level was decreased (7.47 
± 0.96 vs 9.51 ± 1.33, p < 0.05); and thrombocytopenia (82.50 ± 45.85 vs 179.8 ± 56.13, p < 0.05) was characteristic 
for non-survivors. The plates-to-leucocytes ratio in patients who died during hospitalisation was 3.01 ± 2.89. For patients 
who survived hospitalisation it was 15.10 ± 10.86 (p = 0.0069). Similar results were achieved when comparing patients 
who died during hospitalisation 3.01 ± 2.89 vs patients who survived until 2019 16.94 ± 12.62 (p = 0.004662).
Conclusion. Morphology is recommended as the key diagnostic test in predicting mortality risk in patients with IE. The 
plates-to-leucocytes ratio is also a significant marker of mortality. Prompt identification and close monitoring of risk 
factors may prevent a higher mortality rate in IE.
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Introduction
Infective endocarditis (IE) is a disease that is still associa-
ted with high morbidity and mortality. The most frequently 
indicated risk factors are: a prosthetic valve or prosthetic 
material used for cardiac valve repair, transcatheter-
-implanted prostheses and homografts, previous IE history, 
untreated cyanotic congenital heart disease (CHD), and 
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CHD treated with palliative shunts, conduits or other pros-
theses [1]. Wallas et al. found in-hospital mortality of 18% 
and mortality at six months of 27%. The commonly indica-
ted risk factors were not found to be predictors of adverse 
events in this study. Abnormal white cell count, serum 
albumin concentration, serum creatinine concentration, 
cardiac rhythm, the presence of two major Duke criteria, 
or visible vegetation were associated with a poor progno-
sis [2]. Alkhawam et al. [3] identified an overall mortality 
rate of 20.1% in patients with IE, and a readmission rate 
within 30 days of discharge of 21.5%. The most common 
organisms identified were Staphylococcus aureus (43.7%), 
viridans streptococci (17%), and Enterococcus (14.7%) [3]. 
Cresti et al. reported that in-hospital mortality was 24%. In-
dependent predictors of mortality were older age, S. aureus 
infection, heart failure, septic shock, and persistent bacte-
remia. In an Egyptian population, the causes of mortality 
(38.7%) included congestive heart failure (CHF), sepsis, 
surgery-related stroke, cerebral haemorrhage, pulmonary 
embolism, sudden cardiac death, and hyperkalemia [4]. 
Differing experiences in IE and the diversity of markers of 
high mortality highlight the importance of identifying new 
risk factors, as well as of controlling and monitoring existing 
risk factors, for IE in the local population.
Material and methods
21 patients (10 male, 47.62%) who met the modified Duke 
criteria for definite infective endocarditis and who were 
hospitalised in the Cardiology Department between January 
2018 and January 2019 were retrospectively analysed. 
Cardiovascular implantable electronic device-related IE 
concerned nine patients (42.9%), native valve-related IE 
concerned seven patients (33.3%), and prosthetic valve-
-related IE concerned seven patients (33.3%). In clinical 
characterisation, atrial fibrillation affected seven patients 
(33.3%), hypertension 17 patients (80.96%), coronary 
artery disease 10 patients (47.6%), myocardial infarction 
eight patients (38.1%), diabetes nine patients (42.9%), 
and chronic obstructive pulmonary disease 2 patients 
(9.52%). The clinical characteristics of the patients are 
set out in Table 1.
Statistical analysis
All data was expressed as mean ± standard error (SE). 
Variables were analysed with chi-square and Fisher’s 
exact tests, and continuous variables with a Mann-Whit-
ney test. A p-value < 0.05 was identified as statistically 
significant.
Table 1. Clinical characteristics of patients hospitalised because of infective endocarditis (IE)
Clinical characteristic Patients who died during 
hospitalisation




CIED IE 2 3 4
Native valve IE 2 1 4
Prostethic valve IE 2 1 4
Hypertension 4 4 9
Diabetes mellitus 1 3 5
Mitral prosthesis 0 1 2
Aortic prosthesis 2 1 2
Biological prosthesis 1 0 4
Synthetic prosthesis 0 1 0
Mitral regurgitation 2 3 3
Tricuspid regurgitation 5 2 4
Atrial fibrillation 3 3 1
Coronary artery disease 3 3 4
Myocardial infarction in history 2 3 3
Sepsis in history 1 0 3
Dental caries 1 0 3
Abdominal surgery in history 2 0 6
COPD 0 0 2
CIED — cardiovascular implantable electronic device; COPD — chronic obstructive pulmonary disease
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Results
In-hospital mortality was 28.6%, ambulatory mortality was 
23.81%, and total mortality was 52.4%. Patients who survi-
ved IE were younger than those who died, both in hospital 
and at home (66.7 ± 19.8 vs 70.8 ± 11.6 vs 73 ± 13.8 
respectively, p > 0.05). Heart failure was diagnosed in 
14 patients (66.6%). Left ventricular ejection fraction 
was lowest in patients who died at home, 35 ± 22.9, 
compared to living patients 52.7 ± 10 and those who died 
during hospitalisation 43 ± 21.2 (p > 0.05). A pathogen 
was identified in 14 patients, including four who survived. 
The most common was Staphyloccoci spp. 6/14 (42.8%), 
followed by Streptococci spp. 4/14 (28.6%), Klebsiella 
pneumonie 3/14 (21.4%) and Enterococcus fecalis 2/14 
(14.3%). In antibiotic therapy, vancomycine was the most 
frequently used (14/21; 66.6%) (Table 2). Transoesop-
hageal echocardiography was performed in all patients: 
vegetation was visible in 10/21 (47.6%) who died, and in 
8/21 (38.1%) who survived.
The most important feature that identified patients 
who died during hospitalisation was morphology, while 
C-reactive protein did not do so (Table 3) (p < 0.05). 
Plates-to-leucocytes ratio in patients who died during 
hospitalisation was 3.01 ± 2.89 compared to patients 
who survived hospitalisation 15.10 ± 10.86 (p = 0,0069). 
Similar results were achieved when we compared patients 
who died during hospitalisation 3.01 ± 2.89 vs patents 
who survived until 2019 16.94 ± 12.62 (p = 0.004662).
Discussion
Infective endocarditis is a disease difficult to diagnose in out-
-hospital settings and still results in high mortality. The ana-
lysis performed in our centre adds a relevant insight into IE.
In our study, total mortality was relatively high at 
52.4%, as was in-hospital mortality at 28.6%. Delahaye 
et al. [5] indicated that the in-hospital death rate was 
17% and was lower in operated patients (14.4% vs 19.3%, 
p > 0.05) [5]. Ternhag et al. [6] performed data analysis 
Table 2. Antibiotic therapy in patients with infective endocarditis
Antibiotic Patients who died  
during hospitalisation
Patients who died at home  
after hospitalisation
Patients who survived
Vancomycin 3 3 8
Gentamycin 4 2 3
Cilastatin + imipenem 1 0 2
Cloxacillin 2 4 1
Rifampicin 2 2 3
Ciprofloxacin 0 2 1
Ceftazidime 0 0 1
Ceftriaxone 1 2 3
Fluconazole 1 0 2
Teicoplanin 0 0 1
Meropenem 0 0 2
Sulfamethoxazole, trimethoprim 0 0 1
Piperacillin, tazobactam 0 1 1
Ampicillin 0 0 1
Table 3. Blood tests in patients with infective endocarditis
Blood test Patients who died  
during hospitalisation
Patients who died at home  
after hospitalisation
Patients who survived p-value
CRP [mg/L] medium 166.41 ± 122.71 143.02 ± 95.00 118.63 ± 95.14 0.205
WBC [thousand/μL] 35.39 ± 14.36 16.83 ± 13.25 12.02 ± 4.67 0.0068
Haemoglobin [g/dL] 7.47 ± 0.96 8.94 ± 2.37 9.51 ± 1.33 0.032
PLT [thousand/μL] 82.50 ± 45.85 155.4 ± 99.53 179.8 ± 6.13 0.025
eGFR [ml/min/1.73 m2] 17.5 ± 5.75 21.2 ± 11.8 38.4 ± 28.5 0.033
CRP — C-reactive protein; WBC — white blood count; PLT — platelets; eGFR — estimated glomerular filtration rate
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between 1997 and 2007. They found the 30 days all-cause 
crude mortality rate to be 10.4% and the standardised 
mortality ratio (SMR) was 33.7 (95% confidence interval 
[CI]: 31.0–36.6) [6]. In the literature, the early mortality 
has been found to be 14% to 31%, while late mortality rates 
after a five-year follow-up ranged from 25% to 60% [7].
Many risk factors of mortality in IE have been indicated. 
Delahaye et al. [5] found that a history of heart failure (odds 
ratio [OR]: 2.65), a history of immunosuppression (OR: 3.34), 
insulin-requiring diabetes mellitus (OR: 7.82), left-sided IE 
(OR: 1.97), heart failure (OR: 2.19), septic shock (OR: 4.33), 
lower Glasgow Coma Scale score (OR: 4.09), cerebral ha-
emorrhage (OR: 9.46), and higher C-reactive protein level 
(OR: 2.60) were all risk factors of mortality in IE. In our study, 
none of these risk factors reached statistical significance [5].
Platelets play an important role in the pathogenesis of 
endocarditis and are sensitive monitors of the systemic 
host response to sepsis and the severity of thrombocyto-
penia and in predicting six-month mortality. Thrombocy-
topenia at day 8 indicated an impaired host response to 
sepsis and predicted increased mortality. Sy et al. [8, 9] 
recommended empirical antistaphylococcal therapy in 
patients with thrombocytopenia because of the strong 
association between baseline thrombocytopenia and Stap-
hylococcus aureus infection [8, 9]. Experimentally induced 
thrombocytopenia has been associated with more severe 
disease in animal models [10]. In our study, the platelets 
count was significantly lower in non-survivors. The most 
frequently observed pathogens were Staphylococcus spp. 
and vanocomycine was mainly used in survivors, whereas 
cloxacillin was mainly used in non-survivors.
Rostagno et al. [11] identified that hospital mortality 
was closely related to age, clinical and laboratory evidence 
of advanced septic condition (temperature > 38°C, leuko-
cytosis and creatinine > 2.0 mg/dL) and haemodynamic im-
pairment [11]. In our study, white blood cells elevation and 
acute kidney failure with low estimated glomerular filtration 
rate (eGFR) was associated with both in-hospital and overall 
mortality rates in IE. We observed that leukocytosis was 
significantly higher in non-survivors, whereas haemoglobin 
level was severely decreased. We also evaluated whether 
plates-to-leucocytes ratios (PLRs) were significant markers 
of mortality. We identified PLRs as being strong risk factors 
of mortality in IE. Zencir et al. [12] showed that a higher 
PLR may predict in-hospital mortality in patients with IE, 
and that PLRs over 191.01 predicted in-hospital mortality 
with 56.3% sensitivity and 81.4% specificity [12].
The identification of risk factors, and close monitoring 
using simple parameters such as WBC, haemoglobin level, 
and platelets counts, may prevent a high mortality rate.
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Streszczenie
Wstęp. Infekcyjne zapalenie wsierdzia (IE) jest chorobą charakteryzującą się wysoką chorobowością i śmiertelnością. 
Zidentyfikowano liczne czynniki ryzyka śmiertelności w IE.
Materiał i metody. Dwudziestu jeden hospitalizowanych pacjentów z rozpoznanym IE w okresie od stycznia 2018 roku do 
stycznia 2019 poddano analizie retrospektywnej. Dane przedstawiono jako średnie z odchyleniem standardowym, wykona-
no testy: χ2, Fishera i Mann-Whitneya. Współczynnik prawdopodobieństwa p poniżej 0, 05 uznano za statystycznie istotny.
Wyniki. Ogólna śmiertelność wynosiła 52,4%, natomiast wewnątrzszpitalna 28,6%. Pacjenci z IE, którzy zmarli, byli 
w starszym wieku w porównaniu z tymi, którzy przeżyli (66,7 ± 19,8 v. 70,8 ± 11,6). Gronkowce i paciorkowce były naj-
częstszymi patogenami u pacjentów z IE; stanowiły 71,4% przypadków. Najważniejszą cechą, która odróżniała pacjentów 
zmarłych w przebiegu IE, była morfologia krwi. Większa liczba białych krwinek (35,39 ± 14,36 v. 12,02 ± 4,67; p < 
0,05), niższe stężenie hemoglobiny (7,47 ± 0,96 v. 9,51 ± 1,33; p < 0,05) i płytek krwi (82,50 ± 45,85 v. 179,8 ± 56,13; 
p < 0,05) były charakterystyczne dla osób, które zmarły w przebiegu IE. Stosunek trombocytów do leukocytów u pacjen-
tów zmarłych podczas hospitalizacji wynosił 3,01 ± 2,89, w porównaniu z osobami, które przeżyły, u których wynosił 
15,10 ± 10,86 (p = 0,0069). Podobne wyniki otrzymano, kiedy porównano pacjentów zmarłych w trakcie pobytu w szpi-
talu — 3,01 ± 2,89 z pacjentami, którzy przeżyli do 2019 roku — 16,94 ± 12,62 (p = 0,004662).
Podsumowanie. Morfologia okazała się kluczowym badaniem dodatkowym umożliwiającym prognozowanie ryzyka 
śmiertelności w grupie pacjentów z IE. Stosunek liczby trombocytów i leukocytów jest również ważnym markerem 
śmiertelności. Identyfikacja oraz uważne monitorowanie czynników ryzyka może się przyczynić do obniżenia wysokiego 
ryzyka śmiertelności w IE.
Słowa kluczowe: infekcyjne zapalenie wsierdzia, czynniki ryzyka infekcyjnego zapalenia wsierdzia, śmiertelność  
w infekcyjnym zapaleniu wsierdzia
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